Celikalim | 124916-54-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: Celikalim
• 英文别名: 2-[(3S,4R)-3-hydroxy-2,2-dimethyl-6-(trifluoromethoxy)-3,4-dihydrochromen-4-yl]-3H-isoindol-1-one
• CAS: 124916-54-7
• 化学式: C₂₀H₁₈F₃NO₄
• 分子量: 393.4
• InChiKey: ZORATYFUTXFLJS-SJORKVTESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  28
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  59
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• Novel antihypertensive benzopyran derivatives
  申请人：AMERICAN HOME PRODUCTS CORPORATION

  公开号：EP0314446A2

  公开（公告）日：1989-05-03

  Disclosed herein are novel benzopyrans or pharmaceutically acceptable salts thereof having pharmacological activity, to processes for preparing them, to pharmaceutical compositions containing them, and to their use in the treatment of hypertension. The benzopyrans have the formula wherein R1 is trifluoromethoxy or β,β,β-trifluoroethoxy, and R2 and R3 are each independently hydrogen or defined groups. Intermediates are also disclosed.

  本文公开了具有药理活性的新型苯并吡喃类化合物或其药学上可接受的盐、制备它们的工艺、含有它们的药物组合物以及它们在治疗高血压中的用途。这些苯并吡喃具有如下式子 其中 R1 是三氟甲氧基或 β，β，β-三氟乙氧基，R2 和 R3 各自独立地是氢或定义基团。还公开了中间体。
• Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage
  申请人：Stephenson T. Diane

  公开号：US20050009733A1

  公开（公告）日：2005-01-13

  The present invention provides compositions and methods for the treatment of central nervous system damage in a subject. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic condition or a central nervous system traumatic injury comprising the administration to a subject of a potassium ion channel modulator in combination with a cyclooxygenase-2 selective inhibitor.

  本发明提供了治疗受试者中枢神经系统损伤的组合物和方法。更具体地说，本发明提供了一种用于治疗中枢神经系统缺血性疾病或中枢神经系统创伤性损伤的组合疗法，包括向受试者施用钾离子通道调节剂与环氧合酶-2 选择性抑制剂。
• Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels
  申请人：Herlands Louis

  公开号：US20070026079A1

  公开（公告）日：2007-02-01

  Provided are methods of increasing K ATP channel activity in the hypothalamus of a mammal, methods of reducing glucose production in a mammal, methods of reducing peripheral glucose levels in a mammal, methods of reducing triglyceride levels in a mammal, methods of reducing very low density lipoprotein (VLDL) levels in a mammal, methods of methods of reducing gluconeogenesis in the liver of a mammal, methods of treating metabolic disorders such as diabetes, hyperglycemia, insulin resistance, glucose intolerance, metabolic syndrome and/or obesity, and methods of increasing glucose production and peripheral glucose levels in a mammal. Also provided are methods of treating heart failure, ischemia, coronary heart disease, familial lipoprotein lipase deficiency, hypopituitarism, hyperlipidemia, hypertriglyceridemia, hyperVLDLemia, atherosclerosis, hypercholesterolemia, hypertension, polycystic ovary syndrome, gonadotropin deficiency and/or amenorrhea.
• Modulation of Hypothalamic Atp-Sensitive Potassium Channels
  申请人：Rossetti Luciano

  公开号：US20090012067A1

  公开（公告）日：2009-01-08

  Provided are methods of increasing K ATP activity in the hypothalamus of a mammal, methods of reducing glucose production and peripheral blood glucose levels in a mammal, methods of inhibiting gluconeogenesis in the liver of a mammal, and methods of increasing glucose production and peripheral blood glucose levels in a mammal.
• US4925839A
  申请人：——

  公开号：US4925839A

  公开（公告）日：1990-05-15